Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Broggini

Showing results (101-110 of 114) with videos related to

Pageof 12
Sort By:
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLCMassimo Moro, Elisa Caiola, Monica Ganzinelli, et al.
Clinical Lung Cancer|July 24, 2018
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of CarcinomaMartina Imbimbo, Milena Vitali, Alessandra Fabbri, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Nature Communications|July 31, 2021
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancerNour Ghaddar, Shuo Wang, Bethany Woodvine, et al.
Journal of Clinical Medicine|August 6, 2020
Predicting the Role of DNA Polymerase β Alone or with <i>KRAS</i> Mutations in Advanced NSCLC Patients Receiving Platinum-Based ChemotherapyMaria Francesca Alvisi, Monica Ganzinelli, Helena Linardou, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2018
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor modelsAnais Del Curatolo, Fabiana Conciatori, Ursula Cesta Incani, et al.
Scientific Reports|November 18, 2015
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)Monica Ganzinelli, Eliana Rulli, Elisa Caiola, et al.
Clinical Lung Cancer|January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialClaudio Vernieri, Diego Signorelli, Giulia Galli, et al.
Oncogene|August 5, 2018
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsAnna Tessari, Kareesma Parbhoo, Meghan Pawlikowski, et al.
Pageof 12

Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Oncotarget|September 30, 2015
KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapyMirko Marabese, Monica Ganzinelli, Marina C Garassino, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 28, 2018
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLCMassimo Moro, Elisa Caiola, Monica Ganzinelli, et al.
Clinical Lung Cancer|July 24, 2018
RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of CarcinomaMartina Imbimbo, Milena Vitali, Alessandra Fabbri, et al.
The Lancet. Oncology|July 26, 2013
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trialMarina Chiara Garassino, Olga Martelli, Massimo Broggini, et al.
Nature Communications|July 31, 2021
The integrated stress response is tumorigenic and constitutes a therapeutic liability in KRAS-driven lung cancerNour Ghaddar, Shuo Wang, Bethany Woodvine, et al.
Journal of Clinical Medicine|August 6, 2020
Predicting the Role of DNA Polymerase β Alone or with <i>KRAS</i> Mutations in Advanced NSCLC Patients Receiving Platinum-Based ChemotherapyMaria Francesca Alvisi, Monica Ganzinelli, Helena Linardou, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 11, 2018
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor modelsAnais Del Curatolo, Fabiana Conciatori, Ursula Cesta Incani, et al.
Scientific Reports|November 18, 2015
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)Monica Ganzinelli, Eliana Rulli, Elisa Caiola, et al.
Clinical Lung Cancer|January 9, 2019
Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME TrialClaudio Vernieri, Diego Signorelli, Giulia Galli, et al.
Oncogene|August 5, 2018
RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patientsAnna Tessari, Kareesma Parbhoo, Meghan Pawlikowski, et al.
Pageof 12